A Look At AstraZeneca’s Research Pipeline
Investors have a lot to watch for in AstraZeneca’s (AZN) research pipeline in the second fiscal quarter. The company expects a data readout for Lynparza in an ovarian cancer indication. A regulatory decision is expected for Tagrisso in the European Union for lung cancer.